Luminopia is a pioneering brand that is revolutionizing the treatment of neuro-visual disorders. With around 15 million Americans experiencing vision loss caused by brain deficiencies, Luminopia recognizes the need for targeted therapies that address these conditions at their root cause. Traditional methods have fallen short in effectively treating these deficits, leaving a significant unmet need in the market.

Luminopia's innovative approach involves the development of software products that generate therapeutic visual stimuli and deliver them to patients through a virtual reality headset. By stimulating the brain through the eyes, Luminopia's treatments have shown promising results, particularly in the treatment of amblyopia (lazy eye). This success serves as proof-of-concept for their broader platform.

Through their dedication to advancing the field of neuro-visual treatment, Luminopia has garnered accolades, including FDA approval for their VR-based digital therapeutics. These breakthroughs have caught the attention of healthcare professionals and garnered media coverage. With a mission to pioneer a new class of treatments for neuro-visual disorders, Luminopia is leading the way towards a brighter future for patients experiencing vision loss